Therapeutics and Clinical Risk Management (Dec 2015)

Docetaxel-related interstitial pneumonitis

  • Wang CJ,
  • Chang HT,
  • Chang CY

Journal volume & issue
Vol. 2015, no. Issue 1
pp. 1813 – 1816

Abstract

Read online

Chung-Jen Wang, Hou-Tai Chang, Cheng-Yu Chang Division of Chest Medicine, Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan Abstract: Docetaxel (Taxotere®) is an agent that is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer. In recent years, docetaxel-related interstitial lung disease (ILD) has been reported in several case series studies. The onset of ILD occurred ~10–20 days (median time: 18 days) after docetaxel administration. Here, we reported the case of a patient who had pulmonary toxicity of ILD within 3 days after using a relatively low-dose docetaxel administration. Although some articles have described patients who progressed to respiratory failure and needed intubation, this patient responded well to steroid treatment and discontinued docetaxel administration. Keywords: docetaxel, interstitial lung disease

Keywords